The FDA’s final decision on Aradigm Corp.’s (ARDM) New Drug Application for Linhaliq is expected to be announced on January 26, 2018.The Company is seeking approval of Linhaliq for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic infections with Pseudomonas aeruginosa (P. aeruginosa).Linhaliq is composed of a mixture of liposome encapsulated and unencapsulated Ciprofloxacin, a widely prescribed antibiotic that is available in oral and intravenous formulations.ARDM closed Tuesday’s (Dec.26) trading at $5.59, up 4.88%.